Erwin Grussie
Hematology · Los Angeles, CANPI 1679917561
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Exelixis Inc. at 43.6% of the total. Reporting peaked in 2023 at $1,068 and has fallen 56.3% since, to $467 in 2025. That places this record below the midpoint for hematology clinicians in CA, where the typical reported total is $4,615.
Across 50 payments — averaging $55.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$1K
- Pfizer$131
- Astellas Pharma US Inc$125
- AstraZeneca$122
- Ipsen Biopharmaceuticals, Inc$118
- Sanofi$111
- plus $944 from 22 others
Across 87 payments — averaging $5733.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$227K
- Astrazeneca UK Limited$99K
- Astellas Pharma Global Development$64K
- Genentech, Inc.$56K
- Myriad Genetic Laboratories, Inc.$29K
- AstraZeneca$19K
- plus $3K from 1 others
What the payments were for
- Food & beverage$2,70698%
- Education$462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 4 | $1,200 |
| Pfizer | 6 | $131 |
| Astellas Pharma US Inc | 1 | $125 |
| AstraZeneca | 1 | $122 |
| Ipsen Biopharmaceuticals, Inc | 1 | $118 |
| Sanofi | 1 | $111 |
| Jazz Pharmaceuticals Inc. | 1 | $110 |
| Seagen Inc. | 5 | $102 |
| Amgen | 3 | $96 |
| Daiichi Sankyo Inc. | 3 | $86 |
| Merck | 3 | $56 |
| Baxter Healthcare | 1 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Novartis | 2 | $47 |
| GSK | 2 | $46 |
| Bayer | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $28 |
| Bristol Myers Squibb | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| EMD Serono, Inc. | 1 | $23 |
| Pulmonx Corporation | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Tempus AI, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,752 in reported general payments places this provider in the 45th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 45 | $705,353 |
| TagrissoOsimertinib Mesylate | 23 | $374,624 |
| BrukinsaZanubrutinib | 23 | $327,787 |
| XtandiEnzalutamide | 30 | $311,372 |
| Abiraterone Acetate | 87 | $160,225 |
| Imatinib Mesylate | 13 | $94,017 |
| EliquisApixaban | 99 | $74,705 |
| OrgovyxRelugolix | 27 | $71,552 |
| Anastrozole | 96 | $1,748 |
| Raloxifene Hcl | 18 | $715 |
| Tamoxifen Citrate | 43 | $676 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 51 | $648 |
| Hydroxyurea | 45 | $548 |
| Prochlorperazine Maleate | 54 | $543 |
| Ondansetron Hcl | 38 | $508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $47 | $705,35345 claims |
| AstraZenecaTagrisso | $122 | $374,62423 claims |
| Astellas Pharma US IncXtandi | $125 | $311,37230 claims |
| PfizerEliquis | $131 | $74,70599 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $24 | $71,55227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 178 hematology providers in California.
Other hematology in Los Angeles
- Doris QuonLos Angeles$1.5M
- Ilene WeitzLos Angeles$631K
- Caroline PiatekLos Angeles$391K
- Anil TulpuleLos Angeles$79K
- Imran SiddiqiLos Angeles$59K
- Carol KasperLos Angeles$58K
- Everett MeyerStanford$2.1M
- Amrita KrishnanDuarte$671K
- Vinod PullarkatDuarte$576K
- Hope RugoSan Francisco$537K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.